Table 3.

The relationship between percent change in LS, FN, and TH BMD (dependent variable) among the last denosumab injection (DXA2) and follow-up (DXA3) and patient-related factors (independent variables) by using multivariable regression models

Patient-related factors	LS BMD change (%)		FN BMD change (%)		TH BMD change (%)
	Coefficient (95% CI)	p value	Coefficient (95% CI)	p value	Coefficient (95% CI)	p value
Age (per 1 year increase)	− 0.05 (− 0.18 to 0.08)	0.461	0.03 (− 0.08 to 0.13)	0.637	− 0.01 (− 0.08 to 0.07)	0.944
BMI (per 1 kg/m2 increase)	− 0.02 (− 0.30 to 0.26)	0.904	− 0.03 (− 0.26 to 0.20)	0.782	− 0.25 (− 0.42 to − 0.07)	0.006
Prior vertebral Fx	− 0.87 (− 3.95 to 2.21)	0.577	− 0.84 (− 3.26 to 1.58)	0.492	− 0.18 (− 1.99 to 1.63)	0.842
Any fragility Fx during Dmab	− 1.66 (− 6.22 to 2.89)	0.471	− 1.49 (− 5.09 to 2.10)	0.412	− 1.17 (− 3.82 to 1.49)	0.386
BP before Dmab	1.78 (− 0.25 to 3.81)	0.085	1.13 (− 0.54 to 2.80)	0.183	0.92 (− 0.32 to 2.16)	0.145
Total Dmab doses	0.06 (− 0.35 to 0.48)	0.764	− 0.17 (− 0.51 to 0.17)	0.323	− 0.21 (− 0.46 to 0.04)	0.095
ALN or ZOL vs. RIS or NT after Dmab	3.76 (1.76 to 5.81)	< 0.001	2.14 (0.44 to 3.83)	0.014	2.45 (1.22 to 3.75)	< 0.001
LS T-score (start Dmab)	0.26 (− 1.01 to 1.52)	0.687
FN T-score (start Dmab)			0.85 (− 0.57 to 2.26)	0.240
TH T-score (start Dmab)					− 0.67 (− 1.70 to 0.36)	0.200
LS BMD change (during Dmab)	− 0.30 (− 0.47 to − 0.13)	0.001
FN BMD change (during Dmab)			− 0.26 (− 0.41 to − 0.11)	0.001
TH BMD change (during Dmab)					− 0.07 (− 0.24 to 0.09)	0.366

LS, lumbar spine; FN, femoral neck; TH, total hip; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; BMI, body mass index; Fx, fractures; Dmab, denosumab; BP, bisphosphonates; UNL, upper normal limit; 95% CI, 95% confidence interval

Significant p values are shown in bold. All variables listed were included in each regression model